Product Description
Recombinant CA19-9 Antibody [CA19.9/1390R] | 34-073 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: Purified human protein used as the immunogen for the recombinant CA19-9 antibody.
Research Area: Cancer
Tested Application: WB, Flow, IF, IHC-P
Application: Flow Cytometry: 2-4 ug/million cells in 0.1ml
Immunofluorescence: 5-10 ug/ml
Immunohistochemistry (FFPE) : 5-10 ug/ml for 30 min at RT
Prediluted IHC only format: incubate for 30 min at RT (1)
Optimal dilution of the recombinant CA19-9 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein A affinity
Clonality: Recombinant Monoclonal
Clone: CA19.9/1390R
Isotype: IgG, k
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: N/A
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens.